Skip to main content

and
  1. Article

    Open Access

    Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

    Giovanni Caocci, Olga Mulas, Isabella Capodanno in Blood Cancer Journal (2020)

  2. Article

    Open Access

    Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

    The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic ...

    Michele Massimino, Stefania Stella, Elena Tirrò, Chiara Romano in Molecular Cancer (2018)

  3. Article

    Open Access

    SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

    SPARC is a matricellular glycoprotein with growth-inhibitory and antiangiogenic activity in some cell types. The study of this protein in hematopoietic malignancies led to conflicting reports about its role as...

    Cesarina Giallongo, Piera La Cava, Daniele Tibullo, Ignazio Barbagallo in BMC Cancer (2013)